_PRIVATE_LIMITED.webp)
Daymark Pharmaceuticals (India) Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
as on 17-07-2024
- Paid Up Capital ₹ 1.90 M
as on 17-07-2024
- Company Age 26 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.00 M
as on 17-07-2024
- Revenue 41.67%
(FY 2023)
- Profit 112.01%
(FY 2023)
- Ebitda 392.57%
(FY 2023)
- Net Worth 1.52%
(FY 2023)
- Total Assets 70.08%
(FY 2023)
About Daymark Pharmaceuticals (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 1.90 M.
The company currently has active open charges totaling ₹1.00 Cr.
Bhagwandas Batheja and Anjali Batheja serve as directors at the Company.
- CIN/LLPIN
U24232MP1998PTC012746
- Company No.
012746
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Jabalpur, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Daymark Pharmaceuticals (India) Private Limited offer?
Daymark Pharmaceuticals (India) Private Limited offers a wide range of products and services, including Pharmaceutical Medicine, Pharmaceutical Syrup, Dry Syrups, Arthritic Drugs, Anti Cancer Medicines, X-Trant Capsules, Ayurvedic Herbal Syrups & Tonics, Stone Syrup, Dietary Supplements, Omega 3 Capsule.
Who are the key members and board of directors at Daymark Pharmaceuticals (India)?
Executive Team (1)
BB
Bhagwandas Batheja
Managing DirectorAppointment Date: 06-Apr-1998
Status: Current
Board Members(1)
Financial Performance and Corporate Structure Insights of Daymark Pharmaceuticals (India).
Daymark Pharmaceuticals (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 41.67% increase. The company also saw a substantial improvement in profitability, with a 112.01% increase in profit. The company's net worth moved up by a moderate rise of 1.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daymark Pharmaceuticals (India)?
In 2023, Daymark Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
5 years 9 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Feb 2004 | ₹1.00 Cr | Open |
How Many Employees Work at Daymark Pharmaceuticals (India)?
Unlock and access historical data on people associated with Daymark Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Aug 25, 2022, Daymark Pharmaceuticals (India) has raised a total of ₹ 2 M, with the most recent deal valued at ₹ 0.2 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
